1607-Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense followed by PACLitaxel dose de | eviQ
SWOG S 0800 ( NCI CDR 0000636131 ) : addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response ( pCR ) rates in inflammatory or locally